)
)
)
Ziphius is a biotechnology company developing best-in-class vaccines and therapeutics based on its proprietary saRNA and carrier technology (LNP) platform. This platform enables higher and prolonged protein/antigen expression at lower doses (compared to conventional mRNA) with reduced toxicity. It also offers a ‘plug and play' approach, facilitating rapid development, scale-up, and production. These attributes make it well-suited as a platform to enhance pandemic preparedness. Our strategic developments focus on infectious and rare diseases, as well as oncology.
Year Founded
2019
Next catalyst (value inflection) update
Non Human Primates data
Expected time of next catalyst update
Q1 2025
City
Manhattan, New York City
Country
United States
Company CEO or top company official
Chris Cardon, CEO
Development Phase of Primary Product
Pre-Clinical
Lead Product in Development
Prophylactic vaccine for infectious disease (Chlamydia)
Therapeutic Area
Infectious Diseases
Website
http://ziphius.org/